Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
ANVISA issues CGMP to Concord Biotech’s Unit I
Acquisition of exclusive commercialization rights for European markets
The proposed hospital will have a bed capacity of 300 beds and the investment in the project is expected to be around Rs. 500 crore
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
